# Impact GLP-1 Agonists Following Bariatric

Study · id `cardio:ct-nct06132477` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06132477](<https://clinicaltrials.gov/study/NCT06132477>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06132477

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT06132477. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT06132477, source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)
- Started: 2024-02-01 (actual) (ClinicalTrials.gov record NCT06132477, source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT06132477, source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)
- Completion: 2030-07 (anticipated) (ClinicalTrials.gov record NCT06132477, source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06132477, source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06132477-2026-10-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact GLP-1 Agonists Following Bariatric
- Condition: Morbid Obesity
- Condition: Metabolic Syndrome
- Condition: Diabetes Mellitus
- Condition: Hypertension
- Condition: Obstructive Sleep Apnea of Adult
- Intervention (Drug): GLP-1 receptor agonist
- Lead sponsor: University of Missouri-Columbia
- Lead sponsor class: OTHER
- Collaborator: American Society for Metabolic and Bariatric Surgery
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 84307975ea6459f49f32f1bc4634a6af7ae7a4b4841514390ed2980f7b71f81d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
